Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Author(s) -
Christoph Wyen,
Heidy Hendra,
M. Vogel,
Christian Hoffmann,
Heribert Knechten,
Norbert H. Brockmeyer,
Johannes R. Bogner,
JK Rockstroh,
Stefan Eßer,
H. Jaeger,
Thomas Harrer,
Stefan Mauss,
Jan van Lunzen,
Nicole Skoetz,
Alexander Jetter,
C. Groneuer,
Gerd Fätkenheuer,
Saye Khoo,
David Egan,
David Back,
Andrew Owen
Publication year - 2008
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkn029
Subject(s) - efavirenz , nevirapine , cyp2b6 , genotype , reverse transcriptase inhibitor , pharmacology , medicine , genotyping , pharmacogenetics , gastroenterology , biology , virology , sida , viral load , genetics , human immunodeficiency virus (hiv) , antiretroviral therapy , viral disease , cytochrome p450 , metabolism , cyp3a4 , gene
The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and homozygosity on plasma concentrations of efavirenz and nevirapine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom